OCT 27·SEC EDGARLow
Finn Patrick John sold $302K of TWST
Finn Patrick John (President and COO) sold 2,245 shares of Twist Bioscience Corp (TWST) at $134.59 ($0.30M total) on 2026-10-23.
StockNASDAQ · US · USDHealthcare · Diagnostics & Research
$TWST
Twist Bioscience Corp
AlphAI earnings readthird quarter of fiscal 2026 · AUG 3 · NEXT NOV 12Record revenue of $118.4 million in 3QFY26; FY 2026 Revenue guidance raised to $456-$457M; Reiterating Q4 FY26 Adj EBITDA breakevenVerdict: solidRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $TWSTvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 0
- Neutral
- 1
- Bearish
- 0
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $20.7M 17 txs
Leproust Emily M.10× · $9.7M
10b5-1 share of filings59%
Top stories · $TWSTMore →
OCT 22·zerohedge.com
AI Still Needs A Wet Lab To Design Drugs
Citrini Research used Anthropic's AI model Claude to design scorpion antivenom, with Twist Bioscience (TWST) converting designs into testable proteins. The experiment cost $150,000 and yielded 17 promising binders. Investors focus on Twist's potential revenue from AI-driven lab work, with past trades in TWST yielding high returns. The company's AI-related order growth is key for shareholders.
OCT 13·SEC EDGAR
Laponis Adam sold $385K of TWST
Laponis Adam (Chief Financial Officer) sold 2,462 shares of Twist Bioscience Corp (TWST) at $156.30 ($0.38M total) on 2026-10-09.
TWST sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 1 news story mentioning TWST (Twist Bioscience Corp). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent TWST coverage spans financial news, insider activity and market movers.
In the last 30 days, TWST insiders filed 17 SEC Form 4 transactions — no purchases and 17 sales ($20.7M). The most active reporter was Leproust Emily M., Chief Executive Officer, with 10 filings. 59% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving TWST
The insider sale may signal reduced confidence from top management, potentially pressuring the stock.
Potential increase in demand for Twist's lab services as AI design lowers entry barriers for biotech projects.
Insider sale by a top executive may signal reduced confidence and could pressure the stock lower.
Analyst upgrade with a higher price target may attract buying interest.
Positive catalyst from AI‑pharma partnership likely supports further upside.
AlphAI scores every news story that mentions TWST with an AI model for sentiment and relevance, and aggregates insider trades from Twist Bioscience Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $TWST
Score
Finn Patrick John sold $302K of TWST
Finn Patrick John (President and COO) sold 2,245 shares of Twist Bioscience Corp (TWST) at $134.59 ($0.30M total) on 2026-10-23.
1 min read
AI Still Needs A Wet Lab To Design Drugs
Citrini Research used Anthropic's AI model Claude to design scorpion antivenom, with Twist Bioscience (TWST) converting designs into testable proteins. The experiment cost $150,000 and yielded 17 promising binders. Investors focus on Twist's potential revenue from AI-driven lab work, with past trades in TWST yielding high returns. The company's AI-related order growth is key for shareholders.
2 min readLaponis Adam sold $385K of TWST
Laponis Adam (Chief Financial Officer) sold 2,462 shares of Twist Bioscience Corp (TWST) at $156.30 ($0.38M total) on 2026-10-09.
1 min readTWST Maintained by Canaccord Genuity -- Price Target Raised to $
Canaccord Genuity raised its price target for Twist Bioscience (TWST) to $205.00 from $120.00, maintaining a 'Buy' rating. The company's stock is currently trading at $148.22, which is 174.4% overvalued according to GF Value™. Twist Bioscience has a GF Score™ of 70/100, indicating strong growth potential but weaknesses in profitability and valuation. Insiders have sold $119.57 million worth of shares in the last three months.
2 min read
Twist Bioscience Surges as Lilly AI Deal Fuels Bullish Targets
Twist Bioscience (TWST) shares rose 7.38% after announcing a partnership with Lilly for AI-driven drug discovery. Analysts raised price targets to $190–215, citing Twist's role in synthetic biology and AI. The company reported $376.6M revenue, 52% gross margin, and negative EBIT margin of -31.8%. It has a strong balance sheet with $166.8M cash and a current ratio of 2.7. The stock is trading at 23.9x sales and 23x book.
2 min readJefferies initiates Twist Bioscience stock at Hold on valuation
Jefferies initiated coverage on Twist Bioscience (TWST) with a Hold rating and $150 price target, citing premium valuation. The stock trades at $155.65 after a 391% YTD surge. Jefferies notes its market differentiation and AI-driven growth, but warns of high valuation expectations. TWST partners with Eli Lilly's TuneLab for AI/ML drug discovery, while BWS Financial rates it Sell, and Guggenheim reiterates Buy.
2 min read
Twist Bioscience slides as insider sale filings and partnership skepticism pressure sentiment
Twist Bioscience (TWST) fell 6.8% due to insider sales and skepticism about its Lilly TuneLab partnership. The company reported record Q3 revenue of $118.4M and raised full-year guidance. CEO Emily Leproust sold 46,391 shares recently. Analysts' price targets range from $65 to $107.
2 min readLeproust Emily M. sold $919K of TWST
Leproust Emily M. (Chief Executive Officer) sold 4,548 shares of Twist Bioscience Corp (TWST) at an average of $202.15 ($200.44–$207.46, $0.92M total) across 8 trades on 2026-10-05 under a Rule 10b5-1 trading plan.
1 min readWhy is Twist Bioscience stock plunging today?
Twist Bioscience (TWST) shares fell 16.1% to $171.96 after ARK Invest sold $18M worth of shares, marking 21 straight sessions of selling. Insiders also sold shares, and the stock is 42.9% above its fair value estimate. Analysts' average price target is $115.27, suggesting significant downside from the prior close of $205.
2 min read
Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals
Twist Bioscience (TWST) stock rose 10.19% after announcing AI drug discovery deals with Eli Lilly's TuneLab. The company reported $118.4M in quarterly revenue, a $35.1M net loss, and positive operating cash flow of $1.1M. Analysts have raised price targets, with Guggenheim setting it at $212. TWST is seen as a key player in AI-driven biotech.
3 min read